Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Treatment of type 1 diabetes is changing - breakthrough in immune intervention?
Diabetol. Stoffwechs. 6, 98-103 (2011)
Background: Type1 diabetes is an autoimmune disease. An interaction of genetic, immunologic and cell-toxic factors leads to the destruction of insulin producing beta cells in the pancreas of patients with type1 diabetes. A number of immune therapeutics which are to improve the natural progress of the disease are currently evaluated in clinical trials. Methods: Selective research of the literature in databases (pubmed and clinicaltrials. gov, November 2010). Results: Immune therapeutics used in current clinical trials target different mechanisms of the immune system, like antigen presentation (antigen specific therapy, Rituximab), expansion of auto reactive t-cells (anti-CD3), and inflammation via cytokines (IL-1 beta-antagonist). Immune therapeutics are not only applied after diabetes onset adjuvant to intensive insulin therapy, but also as primary prevention in children with a high diabetes risk or as secondary prevention in children, adolescent and adults with positive islet autoantibodies. Conclusion: Adjuvant immune therapeutics and combinations of different therapeutic principles may play an important role for future treatment of type1 diabetes. The evaluation of drug safety will be crucial, so that therapies can be applied in early childhood or as preventive treatment.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Type 1 Diabetes ; Immune Intervention ; Prevention; Beta-cell Function; Genetic Risk; Double-blind; Onset; Insulin; Children; Mellitus; Therapy; Prevent; Trial
ISSN (print) / ISBN
1861-9002
e-ISSN
1861-9010
Journal
Diabetologie und Stoffwechsel
Quellenangaben
Volume: 6,
Issue: 2,
Pages: 98-103
Publisher
Thieme
Publishing Place
Stuttgart
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research (IDF)